Patents by Inventor Andrew Geall

Andrew Geall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12186333
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: January 7, 2025
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Publication number: 20240417740
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Application
    Filed: January 12, 2024
    Publication date: December 19, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew GEALL
  • Publication number: 20240300994
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Application
    Filed: May 15, 2024
    Publication date: September 12, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
  • Publication number: 20240216276
    Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer campuses at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
    Type: Application
    Filed: July 25, 2023
    Publication date: July 4, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew GEALL, Ayush VERMA
  • Patent number: 12018044
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 25, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
  • Publication number: 20240115501
    Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. hese liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew GEALL
  • Publication number: 20240082329
    Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 14, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew GEALL, Ethan SETTEMBRE
  • Patent number: 11913001
    Abstract: Provided is RNA encoding an immunogen is delivered to a large mammal at a dose of from 5 ?g to 100 ?g or at a dose between 0.1 ?g per kilogram body mass of the large mammal and 1.5 ?g per kilogram body mass of the large mammal. Provided is a method of raising an immune response in a large mammal, comprising administering to the large mammal a dose of from 5 ?g to 100 ?g or a dose of between 0.1 ?g of RNA encoding the immunogen per kilogram body mass of the large mammal and 1.5 ?g of RNA encoding the immunogen per kilogram body mass of the large mammal. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: February 27, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11905514
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: February 20, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventor: Andrew Geall
  • Patent number: 11896636
    Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: February 13, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew Geall, Ethan Settembre
  • Patent number: 11891608
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: February 6, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11883534
    Abstract: RNA encoding immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: January 30, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Publication number: 20240016736
    Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
    Type: Application
    Filed: February 27, 2023
    Publication date: January 18, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew GEALL, Ayush VERMA
  • Patent number: 11865080
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: January 9, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11857681
    Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: January 2, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11857562
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: January 2, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11851660
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 26, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11850305
    Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: December 26, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11845925
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 19, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11839686
    Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: December 12, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall